About Frank Troxell

This author has not yet filled in any details.
So far Frank Troxell has created 16 blog entries.

NuMedii Announces Creation of World’s First Single-Cell Sequencing Atlas for Idiopathic Pulmonary Fibrosis by its Collaborators

By |2020-07-21T19:56:24-07:00July 21st, 2020|

SAN MATEO, Calif., July 9, 2020 /PRNewswire/ -- NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world's first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the result of a strategic research collaboration including the Yale School of Medicine, Baylor College of Medicine, Brigham and Women's Hospital, and [...]

NuMedii, Inc. Announces Pharmaceutical Discovery Collaboration For Ulcerative Colitis

By |2020-07-21T19:56:48-07:00July 13th, 2020|

SAN MATEO, Calif., Jan. 15, 2020 /PRNewswire/ -- NuMedii, Inc. today announced a new partnership with a drug delivery company to develop new therapeutics for ulcerative colitis. The collaboration will bring together NuMedii's NM-001 asset for ulcerative colitis and a proprietary delivery technology that enables efficient delivery to the gastrointestinal (GI) tract. "We believe this [...]

NuMedii Names Industry Veteran Heather Arnett, Ph.D. as Vice President of Research

By |2018-11-01T08:54:53-07:00November 1st, 2018|

SAN MATEO, Calif., November 1, 2018 – NuMedii, Inc., today announced the appointment of Heather Arnett, Ph.D., as Vice President, Research. Heather is leading research discovery and early development at NuMedii based on the company’s Artificial Intelligence Drug Discovery (AIDD) technology, which enables the discovery of novel targets and precision drug candidates across a number [...]

NuMedii Announces Research Collaboration With Leading Academic Research Institution to Explore New Targets and Therapeutics for Pancreatitis

By |2018-11-01T09:00:49-07:00November 1st, 2018|

SAN MATEO, Calif., November 1, 2018 – NuMedii, Inc., today announced the formation of a research collaboration with Johns Hopkins School of Medicine with the goal of discovering new targets and therapeutic options for pancreatitis. The collaboration brings together deep clinical expertise with NuMedii’s Artificial Intelligence Drug Discovery (AIDD) technology, which will enable the discovery [...]

NuMedii Announces Strategic Research Collaboration with Two Leading Academic Research Institutions Utilizing Single-Cell Sequencing to Identify Precision Therapeutics for IPF

By |2018-07-10T07:53:58-07:00July 10th, 2018|

SAN MATEO, Calif., July 10, 2018 – NuMedii, Inc., today announced the formation of a strategic research collaboration with Yale School of Medicine and Brigham and Women’s Hospital with the goal of utilizing single-cell sequencing to identify novel precision therapies and biomarkers in idiopathic pulmonary fibrosis (IPF). An orphan disease, IPF is a chronic, progressive [...]

NuMedii Expands Board of Directors and Scientific Advisory Board with the Addition of Two Oncology Experts

By |2018-07-09T09:07:47-07:00June 20th, 2018|

MENLO PARK, Calif., June 20, 2018 – NuMedii, Inc., today announced an expansion of its Board of Directors with the appointment of Athena M. Countouriotis, MD. In addition, Zemin Zhang, PhD, has joined the company’s Scientific Advisory Board. Drs. Countouriotis and Zhang are two industry leaders with expertise in cancer clinical development, and genomics and [...]

World’s Leading Lung Disease Experts Join NuMedii’s Idiopathic Pulmonary Fibrosis Advisory Board

By |2018-07-09T09:11:38-07:00January 8th, 2018|

MENLO PARK, Calif., January 8, 2018 – NuMedii, Inc. today announced the formation of an Idiopathic Pulmonary Fibrosis (IPF) Advisory Board consisting of the world’s leading experts in interstitial lung disease: Naftali Kaminski, MD; David A. Schwartz, MD; Kevin Brown, MD; Toby Maher, MD, PhD; Gisli Jenkins, MD, PhD; Zea Borok, MD; and, Paul Wolters, [...]

NuMedii, Inc. Announces New Partnership To Discover And Advance New Treatments For Idiopathic Pulmonary Fibrosis

By |2017-07-26T10:21:03-07:00April 11th, 2017|

MENLO PARK, Calif., April 11, 2017 – NuMedii, Inc. today announced the formation of a strategic partnership with Three Lakes Partners, LLC, to discover and advance new treatments for idiopathic pulmonary fibrosis (IPF) based on NuMedii’s Big Data intelligence technology. Idiopathic pulmonary fibrosis is a rare chronic progressive and usually fatal interstitial lung disease for [...]

NuMedii, Inc. Wins 2016 Bioprocess International Award For Emerging Company

By |2018-07-09T09:17:19-07:00November 2nd, 2016|

PALO ALTO, Calif., November 2, 2016 – NuMedii, Inc. today announced that it is the recipient of the 2016 BioProcess International Emerging Company Award. The event was held in Boston, MA in October 5, 2016 as part of Biotech Week Boston. “We are pleased to be acknowledged for our Company’s contributions to help discover new uses for medicines [...]

NuMedii, Inc. Announces Third Pharmaceutical Discovery Collaboration

By |2018-07-09T09:19:21-07:00October 4th, 2016|

PALO ALTO, Calif., October 4, 2016 – NuMedii, Inc. today announced the formation of a discovery collaboration with one of the world’s leading pharmaceutical companies to identify new indications for a number of the undisclosed company’s compounds/candidates. The companies will use NuMedii’s predictive Big Data intelligence technology, which enables the discovery of new uses for [...]